The greatest ambition and promise of tissue engineering is to manufacture human organs. Before "madeto-measure" tissues can become a reality [1e3], however, three-dimensional tissues must be reconstructed and characterized. The current inability to manufacture operational vasculature has limited the growth of engineered tissues. Here, free-standing, small diameter blood vessels with organized cell layers that recapitulate normal biological functionality are fabricated using microfluidic technology. Over time in culture, the endothelial cells form a monolayer on the luminal wall and remodel the scaffold with human extracellular matrix proteins. After integration into three-dimensional gels containing fibroblasts, the microvessels sprout and generate extended hollow branches that anastomose with neighboring capillaries to form a network. Both the microfabricated vessels and the extended sprouts support perfusion of fluids and particles. The ability to create cellularized microvessels that can be designed with a diameter of choice, produced by the meter, and undergo angiogenesis and anastomoses will be an extremely valuable tool for vascularization of engineered tissues. To summarize, ultraviolet (UV) photocrosslinkable poly(ethylene glycol) and gelatin methacrylate polymers used in combination with sheathflow microfluidics allow for the fabrication of small diameter blood vessels which undergo neoangiogenesis as well as other developmental processes associated with normal human blood vessel maturation. Once mature, these vessels can be embedded; perfused; cryogenically stored and respond to stimuli such as chemokines and shear stresses to mimic native human blood vessels. The applications range from tissue-on-chip systems for drug screening, characterization of normal and pathologic processes, and creation and characterization of engineered tissues for organ repair.
Introduction
Ideally, engineered human blood vessels should possess tunable dimensions and be free standing so that they can be easily handled and integrated into three-dimensional tissues, as well as be connected to perfusion sources. The constructs should also be amenable to storage for later use and self-sustaining in terms of repair and angiogenesis [1e9] .
Earlier attempts to produce vasculature for tissue models have used de-cellularized cadaver materials as scaffolds [10] , bioprinting of large blood vessels [11] , random outgrowth from endothelial cell spheroid cultures or patterned microchannels [12, 13] . These approaches have been partially successful, yet fail to provide both the range of microvessel diameters found in normal vasculature and the desired control over microvessel placement within a regenerating tissue [14e18] . A key challenge addressed here is the creation of human vasculature that has not only controllable size and cellular architecture but which can produce new angiogenic growth for long term tissue sustainability, a feature that many other technologies, including 3D printing, have yet to fully realize.
Human vasculature forms through a series of developmental processes. Endothelial sprouting from a main vessel (angiogenesis) launches a network of smaller tubular branches each capable of further sprouting to support blood flow (tubulogenesis). Critical junctions (anastomoses) between arterial and venule capillary beds establish a network of arteries/veins, arterioles/venules and capillaries [19] . These three combined processes are essential for tissue maintenance, yet have not been fully replicated in synthetic systems. To date, these processes have largely been accomplished using endothelial spheroid cultures embedded in matrices or prepatterned microchannels and have not yet been observed from free-standing porous synthetic blood vessels.
The objective of this study is to develop an efficient method of constructing human blood vessels that are both representative and complimentary to microscale human blood vessels. Preferably, these fabricated vessels would then support the formation of a primitive network of blood vessels via the natural processes of angiogenesis, tubulogenesis and anastomosis (Fig. 1) , and we sought to characterize the developmental events that occur using our technology. The experimental design begins by creating HEMVs with a desired diameter via hydrodynamic focusing. When seeded into a three-dimensional matrix, the human endothelial microvessels (HEMV) initiate neovascularization which proceeds from angiogenesis through anastomosis. As HEMV technology creates hollow tubular structures with cellular components in place, the ability to immediately perfuse tissue eliminates significant delays associated with tubular development from endothelial networks derived from spheroid cultures. Furthermore, as the HEMV is constructed using a micro-porous [20] , biodegradable material, removal of the scaffold is not required. These advantages, together with the possibility for long term storage of HEMV, make the HEMV technology highly useful for in vitro tissue engineering and tissueon-chip analytical systems.
Materials and methods

Fabrication of microvessels
Microvessels were produced using the microfluidic fabrication method previously described [20e22] with minor modifications. Briefly, poly(ethylene glycol) (PEG) tetrathiol and poly (ethylene glycol) acrylate were purchased from JenKem USA (Allen, TX) and resuspended at a 1:1 M ratio in a 1X phosphate buffered saline solution containing 0.4% Irgacure2959 Sigma Aldrich (St. Louis, MO). Gelatin-methacrylamide (GelMA) has been widely identified as a successful substrate for cell attachment in a multitude of bioengineering applications [23, 24] . Synthesis of GelMA, using porcine-derived gelatin Sigma Aldrich (St. Louis, MO) was performed as previously described [20] and lyophilized gelatinmethacrylamide was included in the previously mixed PEG polymer also at a 1:1 ratio to provide support for cellular attachment. The final concentration of the mixed polymers is 6% w/w (3% poly(ethylene glycol) and 3% gelatin-methacrylamide). Purified protein components include a mixture of fibronectin (50 mg/mL) from Corning (Bedford, MA), rat-tail collagen-1 (75 mg/mL) and hyaluronic acid (18 mg/mL), both from Sigma Aldrich (St Louis, MO), were added to supplement the poly(ethylene glycol)/gelatinmethacrylamide mixture and further support cellular attachment. The outer sheath fluid is 6% PEG, resuspended in phosphate buffered saline. Cells comprising the lumen are resuspended in a 1% non-photo-crosslinkable gelatin solution; while cells placed in the polymer wall are directly added to the polymer solution. Flow rates for were as follows. Outer sheath 90 ml/min; polymer comprising the microvessel wall 29 ml/min and inner lumen flow is 15 ml/min.
Microvessel cryopreservation
Day 8 HEMVs were examined for the ability to recover from cryopreservation in three replicate experiments. Briefly, HEMV were removed from the incubator and immediately transferred to cryovials containing endothelial freezing medium (80% EGM-2, 10% fetal bovine serum, 10% dimethyl sulfoxide). Cryovials were then placed into a freezing chamber and transferred to À80 C overnight. Representative composite image of ten adjacent fields (10X) taken along the length of a single HEMV immunostained with anti-CD31 (green) demonstrates the ability to produce long continuous HEMVs. Scale, 500 mm; inset 50 mm (b) A confluent monolayer of endothelial cells form along the luminal face of the microvessel. 2. Once embedded in a threedimensional matrix, the HEMV develop a primitive microvasculature network through traditional vascularization processes, (c) HEMV angiogenesis, the sprouting of endothelial growths from the original HEMV into an extracellular matrix containing dermal fibroblasts (DAPI-stained nuclei, blue), (d) HEMV tubulogenesis (arrowhead), the hollowing of sprouts to support fluid transport, (e) HEMV anastomosis, a developmental process whereby neighboring sprouts form connections (arrowheads) establishing a closed-loop system for circulation. Scale, (b þ d) 25 mm; (c þ e) 50 mm.
Cryovials were moved to a liquid nitrogen storage dewar and placed into vapor-phase storage for 24 h. HEMV were then thawed at 37 C and immediately placed into complete growth medium and allowed to recover for 24 h at 37 C/5% CO 2 . As a note, suspending HEMV in freezing media and immediately submerging the vial in liquid nitrogen resulted in HEMV structural failure and microvessels were not recoverable. As a positive control for cell death, HEMV were fixed in 10% neutral buffered formalin for 3h and then permeabilized in 1X phosphate buffered saline/0.5% Triton X-100 for 1h, room temp. Cell viability was then examined using Live/ Dead ® assay ThermoFisher Scientific (Grand Island, NY). 20X images were captured and both live and dead cells were counted and plotted as a ratio of total number of cells. For the inflammatory cytokines assay, native or cryopreserved HEMV were treated with either TNF-a (25 ng/mL) or IL-1b (2.5 ng/mL) EMD Millipore (Billerica, MA) for up to 4 h. Cryopreservation was performed as reported above, with cytokine treatment performed on fully recovered HEMV and done in parallel with native microvessels. Real-time quantitative PCR was then used to assay the expression of the Pe and E-selectin genes; with GAPDH as control. The statistical analyses depicted (ANOVA) compare each time point to the matched untreated (0 h) control.
Cell/vascularization experiments
Human cells and growth media
Primary human umbilical vein endothelial cells and primary human dermal fibroblasts were obtained from Lonza (Walkersville, MD) and passaged as recommended. Endothelial growth medium-2 with required supplements (Lonza) was used to grow endothelial cells; while fibroblasts were cultured in DMEM plus 10% fetal bovine serum ThermoFisher Scientific (Waltham, MA). Human primary vascular smooth muscle cells were obtained from ATCC (Manassas, VA) and grown in DMEM/F12 (1:1) with 10% fetal bovine serum plus endothelial growth factor supplement (Sigma), along with the buffers sodium selenite, sodium bicarbonate as recommended. Human vascular pericytes were obtained from ScienCell (Carlsbad, CA) and grown in DMEM/F12 growth medium containing 10% fetal bovine serum. All cells were maintained at 37 C in 5% CO 2 and not used for experimentation beyond passage five. Cells were deemed negative for mycoplasma contamination using MycoProbe R&D Systems (Minneapolis, MN). For microvessel construction, 3 Â 10 7 /mL endothelial cells were used to form the lumen of both single-and multi-cell microvessels; 5 Â 10 6 /mL smooth muscle cells and pericytes were grown in separate cultures and then combined (1:1 ratio) to form the multi-cell microvessels. Multi-cell microvessels containing HUVEC/SMC/HVP were maintained in 50% composite growth media containing 50% EGM2 (Lonza) and 50% DMEM/F12 10%FBS as both SMC and HVP were maintained using this medium.
Antibodies
Monoclonal anti-CD31 (Ab-1) was obtained from ThermoFisher (Waltham, MA) and used at a 1:200 dilution; anti-VE-cadherin was obtained from Santa-Cruz Biotechnology (Dallas, TX). Secondary antibodies were Alexa-488 and Alexa-594 and used at 1:1000 Life Technologies (Grand Island, NY). Anti-collagen IV (clone COL-94) was used at 1:500; anti-laminin was used at 1:100; anti-collagen VII (LH7.2) was used at 1:500, all were obtained from Sigma Aldrich (St. Louis, MO). Anti-porcine-specific collagen I/III (C7510-18Q) was used at 1:25 as recommended by manufacturer USBiological (Salem, MA 
Confocal microscopy/fluorescence quantitation
Image capture was performed using a Nikon laser scanning confocal microscope; Nikon Elements and Adobe Photoshop software were used for image rendering. At least five representative regions of interest were captured over each triplicate experiment and used for quantitative analyses using mean fluorescence intensity determined using ImageJ (NIH) as previously reported [25, 26] . Images of secondary-only negative controls were also collected and used for the purposes of background fluorescence quantitation.
Angiogenesis assays/immunofluorescence
HEMVs were constructed and placed in a CO 2 incubator for 7 days to allow attachment/growth of endothelial cells to the inner luminal face of microvessel. Primary dermal fibroblasts have been shown to facilitate angiogenesis [27, 28] . Therefore, fibroblasts were trypsinized, collected and counted and resuspended at 5 Â 10 5 cells/mL in the hydrogel solutions described below. Using surgical forceps and scissors, microvessels were first cut into shorter lengths then transferred to either 24-well cell culture plates or glass coverslips (coverslips were used for high magnification confocal imaging). Microvessels were then overlaid with solutions of either 4% gelatin-methacrylamide/0.5% photoinitiator (PI) or growth factor reduced Matrigel ® BD Biosciences (San Jose, CA)
containing primary fibroblasts, plus recombinant human vascular endothelial growth factor (rhVEGF, 60 ng/mL) and basic fibroblast growth factor (bFGF, 30 ng/mL). Gelatin-methacrylamide was photopolymerized with UV light (10 mW/cm À2 , 5 s); Matrigel ® was allowed to cure at 37 C for 1hr. Four individual microvessels were used in three separate experiments; the results presented are representative of the biological replicates. Cell-laden microvessels were maintained in growth media and were harvested after 17e21 days unless otherwise indicated; growth media was replaced with fresh media every other day. The above protocol was replicated for HEMV tissue constructs lacking dermal fibroblasts. At the end of the growth period, microvessels were fixed in 4% neutral buffered formalin for 1hr, on ice, followed by permeabilization in 1X phosphate buffered saline/0.5% TritonX-100 for 30 min, on ice. Immunofluorescence was performed as previously reported [25] . Briefly, pre-diluted primary antibody was added to the microvessels and incubated overnight, 4 C. The following day, microvessels were washed 3X in phosphate buffered saline containing 0.05% Tween-20 (PBS-T) and then incubated in secondary antibody for 3 h at room temperature. Finally, DAPI was added at the end of the incubation period for 5 min, and microvessels were extensively washed in PBS-T. Transforming growth factor-beta (TGF-b) is a critical signaling pathway involved in angiogenesis [29] . Therefore, the ability of the TGF-beta pathway to become activated in the HEMV was addressed using purified TGF-beta growth factor. HEMV were serum starved overnight and the following day 5 ng/mL recombinant human TGFb R&D Systems (Minneapolis, MN) was added to HEMV for 10min.
HEMV were then fixed and stained for p-Smad2/3.
Neural glial antigen-2 (NG2) has been previously shown to identify human pericytes at least initially, however in the presence of other cell types such as smooth muscle cells (SMC), pericytes can readily transdifferentiate into SMC [30e33]. To address neural glial antigen-2 (NG2) expression over time, 100 Â 10 3 human vascular pericytes (HVP) were plated at confluency into 24-well plates and maintained either as a mono-or co-culture with smooth muscle cells (SMC). For co-culture, HVP and SMC were mixed at a 1:1 ratio and cultured over a 7 day time course, with daily media changes. Cells from day 1 and day 7 were then fixed in 4% neutral buffered formalin and immunostained simultaneously using either anti-NG2 or anti-a-SMA overnight at 4 C. Five separate 20X images, representing >500 cells were captured for each condition and mean fluorescence intensity was determined using ImageJ (NIH) after normalizing to cell number. The mean fluorescence intensity for NG2 or a-SMA was then plotted for both the mono-or co-culture conditions.
Microvessel cannulation/perfusion experiments
Microvessel perfusion was executed using either of two approaches. For the cannulation experiments, three HEMVs were placed onto separate glass coverslips and, microvessels were overlaid with 4 % gelatin-methacrylamide/0.5 % Igracure-2959 and photopolymerized to immobilize while leaving both termini exposed for cannulation and flow-through. Polycarbonate microcapillaries with dimensions of 80 mm OD/53 mm ID Paradigm Optics (Vancouver, WA) were then manually threaded into the microvessel with the aid of a dissecting microscope while keeping the microvessel hydrated in phosphate buffered saline. Connections were made via threading the capillary into a Luer-Lok tip attached to a 1 mL syringe; the syringe was then loaded into a syringe pump Harvard Apparatus (Holliston, MA). Once the microvessel was cannulated, perfusion was initiated in a stop-flow fashion using a 1 mL/min flow rate; flow was permitted for approximately 2 min. For cannulation experiments, fluorescent Nile Red microparticles (NRmp, 0.52 mm OD) SpheroTech (Lake Forest, IL) were used at 1:100 in 1X phosphate buffered saline. Microvessels were then imaged using confocal microscopy. For perfusion of live cell-laden microvessels, a novel manifold device was constructed by casting polydimethylsiloxane (PDMS) into micro-milled aluminum molds. Once cured, the device was then delaminated, microvessels were removed from the CO 2 incubator and placed in between polydimethylsiloxane pillars of the mold designed to hold the microvessels in place under perfusion. For sealing the devices, a 2 Â 3 inch glass slide Fisher (Pittsburgh, PA) and the polydimethylsiloxane device were plasma coated using a hand-held corona treater from Electro-Technic Products (Chicago, IL) and immediately sealed. The center cavity of the device was filled with 4% gelatin-methacrylamide/0.5% photoinitiator through existing biopsy punches present on the device; gelatin-methacrylamide was then photopolymerized. Inlet cavities were then perfused with endothelial growth media via a micro-peristaltic pump; mediate was recirculated by collecting perfusate from the outlet present on the device. Flow was introduced at 3.1 mL/min, which corresponds to a shear rate of 4.2 dyn/cm 2 of observed shear stress. Manifold devices were transferred to a 37 C/5% CO 2 incubator to maintain cell viability; growth media was also placed into the incubator and left uncapped to permit gas exchange. Perfusion fluids continually recirculated for the times indicated.
COMSOL simulations
Simulations for shear rate and shear flow were performed using finite-element analysis software COMSOL Multiphysics ® (Burlington, MA). Cylindrical models with an extra fine mesh density and diameters of 125 and 100 mm were used as a representation of the microvessel lumen. The parameters for viscosity and density were set at 7.8 Â 10 À4 Pa s and 1007 kg/m 3 , respectively [34] . Calculations for shear rate were carried out for flow rates ranging from 20 mL/ min to 0.5 mL/min.
Quantitative RT-PCR
Total RNA was collected from four individually perfused microvessels in each of three separate experiments by dismantling the polydimethylsiloxane device, harvesting the embedded microvessels and transferring to TRIzol ® reagent Life Technologies (Grand Island, NY). Real-time PCR was performed using a two-step method. RNA was quantitated via NanoDrop™ and 175 mg of total RNA was used for first strand cDNA synthesis via SuperScript IV, which was followed by real-time PCR performed using Power SYBR™ Green master mix, both Life Technologies (Grand Island, NY). Quantitative PCR was performed using an Applied Biosystems instrument (Carlsbad, CA). Analyses of RT-PCR data was performed using the delta-delta Ct method following amplification efficiency analysis using 10-fold dilutions of template cDNA, as previously described [25] . Custom oligos were purchased from Eurofins Genomics (Huntsville, AL). A list of corresponding oligo sequences can be found in Table S1 .
Statistics
All plots, normality testing and statistical analyses were generated using OriginPro 8.5 OriginLab Corporation (Northampton, MA). Asterisks represent results from either two-sided Student's ttest, or ANOVA along with Tukey post-hoc means comparison, where *p < 0.05; **p < 0.01; ***p < 0.001.
Data in brief
Data describing media compatibility experiments for all the relevant cell types, the denuding of the polymeric shell of the microvessel and information regarding microvessel composition and construction have been submitted as a Data in Brief article [35] .
Results and discussion
HEMV fabrication and characterization
The HEMV microfabrication process uses hydrodynamic focusing to surround a continuous flow of suspended cells with a biocompatible hydrogel network [20, 36, 37] . This fabrication process (Fig. S1) incorporates single or multiple cell types into discrete regions of the microvessel during assembly. The length of HEMV produced is limited only by the volume of source materials and, in this study, continuous production of greater than 1 m of HEMV with an inner diameter (I.D.) of 125 mm is obtained in each experimental run. The hydrodynamic focusing technique also facilitates HEMV dimensional tuning by controlling fluid flow rates [20] . In consideration for potential clinical and translational applications, an outer diameter (O.D.) of 250 mm was selected to obviate the need for specialized handling tools during manipulation.
Human umbilical vein endothelial cells are introduced in the lumen of the HEMV during fabrication; cellular attachment to the luminal wall is observed after 3 days. Cell expansion continues until a confluent monolayer is apparent by day 10 (Fig. 2a) . Arterioles contain multiple cell types and are modeled by introducing vascular smooth muscle cells and pericytes into the wall of the microvessel during the fabrication process and are referred to as multi-cell microvessels (MCMV). The endothelial cells line the lumen, while smooth muscle cells proliferate to fill the abluminal wall by days 7e10, with continual growth through days 15e20 ( Fig. 2a; Fig. S2 ) and beyond.
Characterization of the HEMV with laser-scanning confocal immunofluorescence microscopy (LSCM) determines the expression and localization of biomarker proteins in HEMV at various time points. Cells in the luminal wall of the HEMV expressed the endothelial biomarker CD31 and vascular endothelial-cadherin (VE-cadherin) (Fig. 2b and Videos S1, S2). For MCMV, media compatibility assays determined the composite growth media required to support each cell type and a 50/50 composite formulation was used for experimentation, these data can be found in our companion paper [35] . Immunofluorescence staining identifies the cell types incorporated into the MCMV (Fig. S2a) . Alpha-smooth muscle actin (a-SMA) is expressed by both smooth muscle cells (SMC) and pericytes, while neural glial antigen-2 (NG2) has been shown to identify pericytes. Yet, both of these cell types are closely linked and transdifferentiation of pericytes into smooth muscle cells has been observed making cell fate tracking difficult [30,38e41] . Using an in vitro co-culture assay, we address biomarker expression over time (Fig. S2b) and find that NG2 expression, while a viable marker for pericytes in mono-culture, was reduced after 24 h and further reduced by up to 2.5-fold (p < 0.01) day 7 in co-culture with smooth muscle cells, indicating that NG2 expression is likely not suitable to distinguish pericytes from the smooth muscle cells used to create the MCMV. Nevertheless, this multi-compartmental strategy enables the placement of multiple cell types into the microvessel without disrupting the structural integrity of the MCMV during initial cell expansion.
Supplementary video related to this article can be found at http://dx.doi.org/10.1016/j.biomaterials.2017.05.012.
Downstream applications such as in vitro tissue constructs require de novo synthesis of human derived proteins. Therefore, the time-dependent deposition of extracellular matrix proteins including collagens IV, VII and laminin were evaluated. Twelve days after fabrication (T0), striking expression of both human collagen IV (6.5-fold; p < 0.001) and human laminin (>13-fold; p < 0.001) were observed in the walls of the HEMV (Fig. 2c and d) . As a control, skinassociated [42] collagen VII was assayed and found undetectable at T0 and day 12 (Fig. S3a) . Further, a significant decrease (>2-fold; p < 0.001) in the porcine-derived collagen I/III, originally included in the HEMV scaffold, was observed after 30 days, when compared to T0 (Fig. S3b) .
VE-cadherin is a critical biomarker integral for the long-term maintenance of microvessels. Expression of VE-cadherin identifies adherens junction formation in the HEMV by day 10, with persistent expression through day 120 (Fig. 3a) . Further, HEMV maintain their hollow tube morphology (Figs. 2b and 3a) , a feature indispensable for proper vascular perfusion. Taken together, VEcadherin indicates cells establish proper cell-cell junctions; while de novo human collagen IV and laminin accumulation, along with reduced porcine-derived collagen, indicate resident cell populations of the HEMV progressively remodel their environment by depositing matrix proteins and replacing exogenous materials. Remodeling of the surrounding matrix is essential for promoting structural integrity, initiating angiogenesis and subsequent vascular expansion.
HEMV preservation and response to biological cues
Reliable HEMV fabrication and storage could enable a transition toward rapid manufacturing of vascularized tissue constructs. Recently, induced pluripotent stem cell (iPSC) technology has successfully differentiated endothelial cells from dermal fibroblasts [2] . As demand for personalized medicine increases, tailored-HEMV could be prospectively constructed and banked for future use via an iPSC source. To that end, cryopreserved HEMV was evaluated similarly laminin exhibited a 13-fold increase in expression (p < 0.001) when compared to T0 microvessels. Scale, 100 mm.
initially for cell viability and subsequently for the ability of the recovered constructs to exhibit normal endothelial cell functions (Fig. 3bec) . Live/dead staining reveals no statistical change in percentage of dead cells following recovery from cryopreservation.
A critical aspect of functional vasculature is response to inflammatory signals delivered to endothelial cells via circulating inflammatory cytokines [43] . To further characterize the HEMV technology, a response to inflammation assay was measured using quantitative-PCR on both native and cryopreserved day 8 HEMV (Fig. 3dee) . Cytokines such as tumor necrosis factor-alpha (TNF-a) and interlukin-1beta (IL-1b) are critical pro-inflammatory signaling molecules responsible for triggering endothelial expression of leukocyte adhesion genes such as E-selectin. Native or cryopreserved HEMV treated with either TNF-a or IL-1b increased Eselectin production up to a 40-fold increase (p < 0.001) and up to a 12-fold increase (p < 0.001), respectively, when compared to untreated control HEMV. In most cases, E-selectin was strongly elevated 2 h post treatment with reduced expression observed by 4 h. The observed expression was evident either in the presence or absence of cryopreservation; the only statistical significance between those groups was identified following IL-1b (2 h) treatment, where the cryopreserved group indicated a slightly more potent Eselectin response (p < 0.01) compared to the native HEMV (2 h). The observed effects are consistent within time frames and concentrations reported for human endothelial cells [44e47] . A similar upregulation of E-selectin protein is exhibited following treatment with TNF-a or IL-1b. P-selectin preferentially responds to the clotting factor thrombin [47, 48] and was not induced over the time course assayed and serves as a negative control. These data provide not only functional assessment regarding gene expression in HEMVs following cryopreservation, but also provide valuable information regarding the ability of both native and cryopreserved HEMV to stimulate genes necessary for leukocyte attachment in response to inflammatory signals.
Endothelial cell proliferation and cell-signaling pathway activation were also assayed to determine if cells in HEMV recapitulate normal cellular functions. To address primary cell proliferation and quiescence following cell integration, the Ki-67 nuclear proliferation marker was assayed. At time zero (T0), >70% of resident endothelial cells are actively undergoing replication evidenced by nuclear expression of Ki-67. The Ki-67 expression is coupled with minimal cell-surface expression of VE-cadherin (Fig. S4a) , indicating that the endothelial cells have not yet exhibited contact inhibition. Once continuous cell-cell contacts are established, Ki-67 expression is reduced 3.5-fold (p < 0.001) and a concomitant potent increase in VE-cadherin is observed at the homotypic cell-cell junctions. This pattern is consistent with the process whereby normal mammalian cells undergo contact inhibition and enter a reversible phase of the cell-cycle (quiescence) to avoid over proliferation.
Furthermore, to validate that cells in the HEMV recapitulate other normal functions, we interrogated the transforming growth factor-beta (TGF-b) signaling pathway as it is directly involved in angiogenesis [29] . Activation of the TGF-b pathway via the surrogate marker phosphorylated-Smad2/3 [49] indicates TGF-b-treated HEMV strongly induces Smad2/3 phosphorylation, resulting in nuclear retention (Fig. S4b) . Consequently, cells present in the HEMV proliferate until confluent, establish cell-cell adherens junctions and activate signaling pathways, which are three significant indicators of a biologically functional blood vessel.
Neoangiogenesis
In the absence of angiogenic potential, incorporation of vasculature alone is insufficient to support complex tissue as simple diffusion is inadequate for nutrient transport beyond 1 mm [50, 51] . Therefore, organized endothelial expansion beyond the primary HEMV is necessary to sustain three-dimensional tissue constructs. We hypothesized that denuding the biopolymeric shell of the HEMV might be required for neoangiogenesis and we successfully denuded day 7 HEMV via collagenase digestion or mechanical disruption [35] .
However, further examination of intact HEMV revealed short protrusions extending into the surrounding biopolymeric shell (Fig. 3a) , which suggested that resident endothelial cells could undergo angiogenic sprouting through the synthetic microvessel wall. Further studies thus focused on supporting the angiogenic potential of the intact HEMV by embedding them in a hydrogel containing normal human dermal fibroblasts to mimic a tissue environment. Endothelial cell-only HEMV provided the opportunity to characterize endothelial expansion and endothelial sprouts easily distinguished from the fibroblasts present in the surrounding gel. Under these conditions substantial endothelial sprouting (Fig. 4aec) was observed when embedding intact HEMV in the presence of primary fibroblasts.
Two different types of hydrogel, both containing dermal fibroblasts, were investigated for incorporation of the HEMV into a model tissue. Growth-factor-reduced Matrigel ® or 4% gelatinmethacrylamide both supported endothelial expansion from the HEMV with no marked difference observed in overall sprouting performance. Matrigel ® slightly increased the average number of endothelial sprouts, though this did not reach statistical significance (p > 0.59). Thus, while maintaining microvessel integrity after removing the polymer walls is feasible [35] , it is not required as the HEMV clearly exhibit prolific neovascularization using asfabricated microvessels. Further, embedded HEMV retain the hollow-tubule morphology, indicating HEMV structural stability (Fig. 4a) . Dimensionally, sprouts are wider closest to the microvessel and narrow to <8 mm in width at sprout termini. Sprout lengths measured from the outer edge of the HEMV to the advancing tip ranged from 50 mm to 1290 mm (Fig. 4c) with a median length of 547 mm; shorter assay times resulted in shorter overall lengths, indicating that 1.3 mm may not be the upper limit of growth. Remarkably, endothelial sprouts were also observed to traverse the synthetic wall of the HEMV (Fig. 4a; Figs. S5aed) , a critical feature essential for vascularization and ultimate tissue integration. Furthermore, observed interactions between neighboring embedded HEMVs, via capillary outgrowth, indicates putative HEMV-HEMV linkages (Fig. S5d) .
Having observed HEMV neoangiogenesis, we next verified that the newly-formed sprouts were hollow tubules. Fig. 4d (center) depicts a representative CD31 þ angiogenic sprout, while flanking insets show representative high-magnification images. Orthogonal laser scanning micrographs confirm the hollow nature of the sprouts with an average luminal diameter of 4±1 mm. Extensive CD31 þ filiopodial projections are observed along the lengths of many sprouts and are indicative of continued endothelial expansion ( Fig. 1d; 4d-e) . Anastomoses among angiogenic sprouts were virtually innumerable (Fig. 4e) , pointing toward terminal development of a complex vascular network. Further, fibroblasts play an integral role in angiogenesis by providing matrix remodeling necessary for endothelial outgrowth, and organized DAPI-labeled fibroblasts were observed upstream of the advancing CD31 þ bifurcated endothelial tip (Fig. S5c) , results consistent with previous observations [27, 28] . The growth status and efficacy of dermal fibroblasts included in the extracellular matrix of HEMV tissue constructs was also assessed. Similar to CD31, we find VE-cadherin expression is maintained on endothelial sprouts derived from HEMV embedded in a fibroblast matrix (Fig. S6a) indicating sprouts support cell-cell adhesions. Using Alexa488-phalloidin to identify cytoskeletal Factin, embedded fibroblasts display a spheroidal morphology at time zero, as expected. By day 5, fibroblasts present in the hydrogel display characteristic bipolar, elongated morphology consistent with viable fibroblast expansion (Fig. S6b) [52] . When fibroblasts were excluded, endothelial sprouting was found to be significantly reduced with only short projections of 27 mm median length observed nearest the HEMV lumen at the time of collection on day 21 (Fig. S6c) . In the absence of fibroblasts, CD31 þ endothelial sprouts failed to exit the polymer wall of the HEMV by the time point assayed, indicating that fibroblasts were integral to the development and maturation of endothelial sprouting derived from the HEMV.
HEMV perfusion and shear stress response
To investigate whether sprouts support perfusion, embedded HEMV were cannulated using polycarbonate capillaries (Fig. S7) . The HEMV remained viable under approximate pressures of 150e2500 Pa without failure and were able to withstand shear stresses up to the flow-rate limits of the peristaltic pump (25 dyn/ cm 2 ). Three distinct regions of interest are used to illustrate perfusion (Fig. S7b) . Insets show that NRmp enter newly formed sprouts, confirming the HEMV are hollow and support fluid transport. However, not all angiogenic sprouts were identical (Fig. S7c) ; NRmp are present in the lumen of CD31 þ positive endothelial sprouts but absent in immature or otherwise occluded sprouts, with NRmp exclusion likely due to ongoing sprout development, as has been previously observed [53, 54] . On average, mature sprouts supporting perfusion were found to outnumber immature sprouts by a ratio of 3:1. Finally, shear stress was investigated to validate the HEMV method of neovascularization ( Fig. S8 ; Videos S3a and b) using both experimentally derived observations as well as COMSOL simulations. Not only does shear stress generate forces that act upon the vessel, but cells undergo morphological changes in response to pulsatile perfusion. Therefore, to illustrate that HEMV support perfusion in a microvessel containing living cells, a novel manifold device [52, 55] in conjunction with a peristaltic pump was used to recirculate either growth media or Nile Red microparticles through individual microvessels.
Genes related to shear stress have been widely investigated, in more rigid models, with links to multiple cell signaling pathways, including TGF-b [56] . TGF-b itself has pervasive effects upon cellular growth dynamics and can effect proliferation, differentiation, migration and blood vessel maturation. TGF-b stimulates various response genes called Smads that either propagate or inhibit the TGF-b signal. Smad6 and Smad7 are inhibitory-Smads (ISmads). Smad6 limits the signaling of the bone morphogenetic protein (BMP) receptor, while Smad7 predominantly inhibits TGF-b [57e59]. Changes in expression of other genes such as Krüppel-like factor-2 (KLF2); chemokine receptor-4 (CXCR-4); sphingosine kinase-1 (SPHK1); sphigosine-1-phosphate phosphatase-1 (SGPP1); and sphingosine-1-phosphate lyase-1 (SGPL1) have also been explored in response to shear stress [60, 61] and are investigated here using live, cell-laden HEMV to in order validate the model. Interestingly, differential gene regulation occurred within a relatively short time frame (1h or 3h) (Fig. 5) suggesting that perfusion has an earlier effect on cellular dynamics than previously reported [61e63]. The most prominent changes are observed in SMAD7, KLF2 and SPHK1 with 3.5-, 4.5-and 3.1-fold increases respectively (p < 0.001). Conversely, SMAD6 and SGPL1 were downregulated 3.8-and 1.7-fold (p < 0.001; p < 0.05), respectively, after 1h of perfusion. Furthermore, the differential effects observed between SMAD6 and SMAD7 under perfusion assays are noteworthy. Shear stress likely targets the BMP pathway for enhanced expression, observed here as relieved repression; while conversely TGF-b activation is inhibited via SMAD7, indicating TGFb may not be required by endothelial cells under shear-stress, an observation supported in other work [64] . Also, the slight repression of SGPL1 observed here is consistent with the increases observed in SGPK1, as SGPL1 functions as a negative regulator of SPHK1.
Finally, genes such as EphrinB2 (EFNB2) and EphB4 (EPHB4) have previously been shown to function as biomarkers capable of differentiating between arterial and venous blood vessels [65e68]. Arterial-derived blood vessels have been shown to express the transmembrane ligand EphrinB2, while venous-derived vessels have been shown to express EphB4, the cognate receptor for EphrinB2. In order to determine if EphrinB2 or EphB4 can be used to distinguish HEMV and MCMV under perfusion, live HEMV or MCMV were exposed to shear stresses for up to 2 h (Fig. 5dee) and RNA was assessed via quantitative RT-PCR. Expression of EphrinB2 was observed increased 2.3-fold (p < 0.01) in MCMV, when compared to static control (0h), while no such upregulation was observed in HEMV under the same perfusion rate. Similarly, in perfused HEMV, EphB4 displayed a more modest, though In summary, results obtained from perfusion experiments using the manifold device show that HEMV support perfusion and respond to shear stress, significantly improving upon in vitro endothelial networks and acellular microchannel conduits used in other applications. Additionally, the EphrinB2 and EphB4 biomarkers distinguish HEMV from MCMV, thus providing biochemical evidence that fabricated microvessels can exhibit differential responses to the appropriate signaling cue, whether from a growth factor for an integral signaling pathway such as TGF-beta or shear stress in response to perfusion.
Conclusions
Technological advances in microfluidics combined with improved biocompatible materials have made microfabrication of human blood vessels a possibility [20e24,52] . Combining a functional vasculature which displays developmental processes to support complex tissue constructs is critical, and many of the developmental process observed in native human blood vessels have been recapitulated using HEMV technology. In summary, biochemical and mechanical analyses illustrate that HEMV support single-or multi-cell attachment and growth; remodel their extracellular matrix by incorporating native human proteins into the vessel wall; remain hollow/porous tubules of the predesigned size and function in a matrix of other cells. In addition, HEMV promote angiogenesis, tubulogenesis and anastomosis together as a single system within a three-dimensional in vitro tissue model. Further, perfused HEMV permit the biochemical analyses of HEMV under various flow conditions. When compared to other constructs, such as decellularized vessel scaffolds, HEMV reduce the potential transfer of donor pathogens, are more comparable in size to human venules/arterioles and are easily positioned into a tissue model. Most notably, the extensive neoangiogenesis observed from embedded HEMV and the capacity for long-term storage underscore the versatility that both freshly prepared and cryopreserved HEMV provide, allowing the user to design, create and store the fabricated HEMV for future use. Concerning neoangiogenesis, importantly we find embedded HEMVs self-vascularize their surrounding ECM eliminating the need to fully 'engineer' tissue vascularization. Rather, the cells present in the HEMV respond to signaling cues that direct where and to what extent angiogenesis should occur, which is more representative of the native state of vascular development. Finally, other technologies such as 3D or microparticles in a recirculated fashion using separate microvessels at 4 dyn/cm 2 . Scale, 50 mm (c) Shear-stress response genes were examined via real-time PCR from growthmedia perfused HEMV. Genes with the most differential regulation include the TGF-b members SMAD6 (downregulated 3.8-fold; p < 0.001) and SMAD7 (upregulated 3.5-fold, p < 0.001). Other observed changes included SPHK1 (upregulated 3.1-fold; p < 0.001) and SGPL1 (downregulated 1.7-fold; p < 0.05). SGPP1 was observed unchanged. (d and e) EphrinB2 or EphrinB4 are biomarkers capable of distinguishing arterial from venous blood vessels, respectively. The effect of perfusion on EphrinB2 and EphB4 gene expression was assessed using either live HEMV or live multi-cell microvessels (MCMV) via real-time PCR. In the arterial-like MCMV, EphrinB2 was observed upregulated 2.3-fold (p < 0.01); while EphB4 was upregulated 1.4-fold (p < 0.03) in venous-like HMEV in response to growth media perfusion. Statistical analyses shown compare the 2 h perfusion group to static perfusion 0 h control microvessels. Error bars depict standard error of the mean (SEM) of 3 biological replicates.
printing, while undoubtedly promising, have yet to produce a human vascularized model that can exhibit long-term viability, extensive angiogenesis, perfusion and blood vessel storage. Thus, HEMV technology provides a level of flexibility and experimental standardization not possible using endothelial spheroid cultures or other microvessel technologies. 
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